Belite Bio (Belite Bio) Dividend Yield % : 0.00% (As of Jun. 24, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Dividend Yield %?

As of today (2024-06-24), the Trailing Annual Dividend Yield of Belite Bio is 0.00%.

The historical rank and industry rank for Belite Bio's Dividend Yield % or its related term are showing as below:

BLTE's Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Dividend Yield % only.

Belite Bio's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-06-24), the Forward Dividend Yield % of Belite Bio is 0.00%.

Belite Bio's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Belite Bio Dividend Yield % Historical Data

The historical data trend for Belite Bio's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Dividend Yield % Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dividend Yield %

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Yield %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Belite Bio's Dividend Yield %

For the Biotechnology subindustry, Belite Bio's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Belite Bio's Dividend Yield % falls into.

Belite Bio Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Belite Bio (NAS:BLTE) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Belite Bio Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Belite Bio's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Dividend Yield %

Comparable Companies

Traded in Other Exchanges

D01:Germany

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.